{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:16Z","timestamp":1791302476341,"version":"4.1.0"},"reference-count":47,"publisher":"American Chemical Society (ACS)","issue":"39","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21907086"],"award-info":[{"award-number":["21907086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019BH088"],"award-info":[{"award-number":["ZR2019BH088"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH210"],"award-info":[{"award-number":["ZR2024MH210"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus and obesity are closely linked metabolic disorders driven by insulin and leptin resistance. Current long-acting therapies capable of addressing both conditions are dominated by incretin-based agents, which primarily achieve efficacy through appetite suppression and are frequently associated with tolerability limitations and metabolic rebound after treatment discontinuation. Alternative strategies that correct underlying signaling defects without suppressing food intake remain lacking. Protein tyrosine phosphatases PTPN1 and PTPN2 act as coordinated intracellular negative regulators of insulin and leptin signaling by dephosphorylating key molecules within the IRS-AKT and JAK2-STAT3 pathways. Although genetic studies have established these phosphatases as attractive therapeutic targets, translation has been hindered by the absence of long-acting inhibitors with robust in vivo efficacy. Here we report the rational design of Y5, a chemically engineered BimBH3-derived peptide analogue that functions as a dual inhibitor of PTPN1 and PTPN2. Fatty-acid conjugation and hapten modification confer high enzymatic potency, enhanced proteolytic stability, strong albumin binding, and prolonged half-life and systemic exposure. Y5 restores cellular insulin and leptin signaling in vitro, leading to coordinated activation of IRS-1, AKT, and STAT3 under resistant conditions. In diabetic db\/db mice, Y5 once-weekly administration induces sustained glycemic control, improves glucose tolerance, and reduces circulating insulin levels, consistent with enhanced insulin sensitivity. In DIO mice, Y5 induces pronounced and sustained weight loss while preserving food intake, demonstrating a potential mechanism distinct from incretin-based therapies. Y5 selectively reduces adiposity, improves hepatic steatosis, and is well tolerated across dosing regimens. These findings establish long-acting dual inhibition of PTPN1 and PTPN2 as a mechanistically distinct therapeutic strategy for T2DM and obesity. By reversing hormone resistance rather than suppressing appetite, Y5 defines an alternative paradigm for achieving long-acting glycemic control and weight loss in vivo.<\/jats:p>","DOI":"10.1021\/acsomega.6c05930","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:01:59Z","timestamp":1790139719000},"page":"59556-59571","source":"Crossref","is-referenced-by-count":0,"title":["The PTPN1\/N2 Peptide\nInhibitor Achieves Potent, Long-Acting\nGlycemic Control and Weight-Loss Dual Efficacy in Mice"],"prefix":"10.1021","volume":"11","author":[{"given":"Yiying","family":"Shi","sequence":"first","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Yang","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxu","family":"Meng","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Amsterdam , , ,","place":["Amsterdam, The Netherlands, 1081HV"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6755-9667","authenticated-orcid":true,"given":"Anton","family":"Feenstra","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Amsterdam , , ,","place":["Amsterdam, The Netherlands, 1081HV"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwen","family":"Gu","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yao","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhen","family":"Dong","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Gong","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-0554","authenticated-orcid":true,"given":"Chuanliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]},{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Gu","sequence":"additional","affiliation":[{"name":"Qingdao University of Science and Technology , , ,","place":["Qingdao, China, 266042"]},{"name":"Ocean University of China , , ,","place":["Qingdao, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100610465604900_cit1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: An update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"issue":"1","key":"2026100610465604900_cit2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist\ncorrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat.\nMed."},{"key":"2026100610465604900_cit3","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation.","year":"2021","edition":"10"},{"issue":"1","key":"2026100610465604900_cit4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss\nand glycemic control with SAR441255, a potent unimolecular peptide\nGLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab."},{"issue":"6","key":"2026100610465604900_cit5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/biomedicines12061320","article-title":"New Developments in\nPharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and\nwithin GLP-1 Receptor Agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"2026100610465604900_cit6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once\nWeekly in Patients\nwith Type 2 Diabetes","volume":"385","author":"Fri\u0301as","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10160","key":"2026100610465604900_cit7","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP\nand GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised,\nplacebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"2026100610465604900_cit8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects\nof subcutaneous tirzepatide versus placebo\nor semaglutide on pancreatic islet function and insulin sensitivity\nin adults with type 2 diabetes: a multicentre, randomised, double-blind,\nparallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet\nDiabetes Endocrinol."},{"issue":"1","key":"2026100610465604900_cit9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy\nand Safety\nof Tirzepatide in Type 2 Diabetes and Obesity Management","volume":"32","author":"Sinha","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"issue":"3","key":"2026100610465604900_cit10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide\nOnce Weekly for the Treatment of\nObesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026100610465604900_cit11","doi-asserted-by":"publisher","first-page":"105791","DOI":"10.1016\/j.ebiom.2025.105791","article-title":"Mazdutide,\na dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated\ncognitive dysfunction: mechanistic insights from multi-omics analysis","volume":"117","author":"Dong","year":"2025","journal-title":"EBioMedicine"},{"issue":"22","key":"2026100610465604900_cit12","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-Weekly Mazdutide\nin Chinese Adults with Obesity or Overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"2026100610465604900_cit13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy\nand Safety of Mazdutide in Chinese Patients\nWith Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled\nPhase 2 Trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"2026100610465604900_cit14","unstructured":"WEGOVY (semaglutide) injection, for subcutaneous\nuse. U.S. FDA, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf."},{"issue":"3\u20134","key":"2026100610465604900_cit15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor\nAgonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"2026100610465604900_cit16","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety\nof Semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front\nEndocrinol (Lausanne)."},{"issue":"3","key":"2026100610465604900_cit17","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic\nreview of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"2026100610465604900_cit18","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound\nafter GLP-1 receptor agonist discontinuation:\na systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"6","key":"2026100610465604900_cit19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-024-00965-1","article-title":"Protein tyrosine phosphatase 1B in\nmetabolic diseases and drug development","volume":"20","author":"Delibegovic\u0301","year":"2024","journal-title":"Nat.\nRev. Endocrinol."},{"issue":"5407","key":"2026100610465604900_cit20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1126\/science.283.5407.1544","article-title":"Increased\ninsulin sensitivity and obesity resistance\nin mice lacking the protein tyrosine phosphatase-1B gene","volume":"283","author":"Elchebly","year":"1999","journal-title":"Science"},{"issue":"14","key":"2026100610465604900_cit21","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1016\/S0021-9258(18)68703-4","article-title":"Characterization\nof the major protein-tyrosine-phosphatases\nof human placenta","volume":"263","author":"Tonks","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"2","key":"2026100610465604900_cit22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1128\/MCB.25.2.819-829.2005","article-title":"Coordinated regulation of insulin\nsignaling by the protein tyrosine phosphatases PTP1B and TCPTP","volume":"25","author":"Galic","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"2026100610465604900_cit23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db17-1485","article-title":"TCPTP Regulates Insulin\nSignaling in AgRP Neurons to Coordinate Glucose Metabolism With Feeding","volume":"67","author":"Dodd","year":"2018","journal-title":"Diabetes"},{"issue":"20","key":"2026100610465604900_cit24","doi-asserted-by":"publisher","first-page":"e175163","DOI":"10.1172\/JCI175163","article-title":"T cell protein tyrosine phosphatase\nattenuates T cell\nsignaling to maintain tolerance in mice","volume":"133","author":"Wiede","year":"2023","journal-title":"J.\nClin. Invest."},{"issue":"3","key":"2026100610465604900_cit25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","article-title":"PTP1B Is an Intracellular Checkpoint that Limits T-cell\nand CAR T-cell Antitumor Immunity","volume":"12","author":"Wiede","year":"2022","journal-title":"Cancer Discovery"},{"key":"2026100610465604900_cit26","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1038\/ncomms4073","article-title":"PTPN2 attenuates T-cell lymphopenia-induced\nproliferation","volume":"5","author":"Wiede","year":"2014","journal-title":"Nat. Commun."},{"issue":"4","key":"2026100610465604900_cit27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/mi.2014.122","article-title":"PTPN2 controls differentiation of CD4+ T\ncells and limits intestinal inflammation and intestinal dysbiosis","volume":"8","author":"Spalinger","year":"2015","journal-title":"Mucosal Immunol."},{"issue":"4","key":"2026100610465604900_cit28","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1021\/acs.jmedchem.2c02003","article-title":"Discovery of Novel PTP1B\nInhibitors with Once-Weekly Therapeutic\nPotential for Type 2 Diabetes: Design, Synthesis, and In Vitro and\nIn Vivo Investigations of BimBH3 Peptide Analogues","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026100610465604900_cit29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/acsmedchemlett.1c00174","article-title":"Discovery of Novel\nPTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2\nProteins with Antidiabetic Potency","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med.\nChem. Lett."},{"key":"2026100610465604900_cit30","doi-asserted-by":"publisher","first-page":"112376","DOI":"10.1016\/j.ejmech.2020.112376","article-title":"Recent advance on PTP1B\ninhibitors and their biomedical applications","volume":"199","author":"Sharma","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"2026100610465604900_cit31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/1568026619666190201152153","article-title":"PTP1b Inhibition, A Promising Approach\nfor the Treatment of Diabetes Type II","volume":"19","author":"Eleftheriou","year":"2019","journal-title":"Curr.\nTop. Med. Chem."},{"issue":"11","key":"2026100610465604900_cit32","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.celrep.2019.08.019","article-title":"Intranasal Targeting\nof Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity\nand Promotes Weight Loss in Obesity","volume":"28","author":"Dodd","year":"2019","journal-title":"Cell Rep."},{"issue":"8","key":"2026100610465604900_cit33","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/oby.2009.444","article-title":"Inhibition of PTP1B by Trodusquemine\n(MSI-1436) Causes Fat-specific Weight Loss in Diet-induced Obese Mice","volume":"18","author":"Lantz","year":"2010","journal-title":"Obesity"},{"issue":"31","key":"2026100610465604900_cit34","doi-asserted-by":"publisher","first-page":"23642","DOI":"10.1074\/jbc.M001063200","article-title":"Down-regulation\nof Insulin Signaling\nby Protein-tyrosine Phosphatase 1B Is Mediated by an N-terminal Binding\nRegion","volume":"275","author":"Dadke","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"13","key":"2026100610465604900_cit35","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.275.13.9792","article-title":"Identification of tyrosine phosphatases\nthat dephosphorylate\nthe insulin receptor. A brute force approach based on \u2033substrate-trapping\u2033\nmutants","volume":"275","author":"Wa\u0308lchli","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"6","key":"2026100610465604900_cit36","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1074\/jbc.275.6.4283","article-title":"Tyrosine dephosphorylation\nand deactivation of insulin receptor substrate-1 by protein-tyrosine\nphosphatase 1B. Possible facilitation by the formation of a ternary\ncomplex with the Grb2 adaptor protein","volume":"275","author":"Goldstein","year":"2000","journal-title":"J. Biol.\nChem."},{"issue":"33","key":"2026100610465604900_cit37","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1074\/jbc.271.33.19810","article-title":"Protein-tyrosine Phosphatase\n1B Is a Negative Regulator of Insulin- and Insulin-like Growth Factor-I-stimulated\nSignaling","volume":"271","author":"Kenner","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"2","key":"2026100610465604900_cit38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/13543784.12.2.223","article-title":"PTP1B inhibitors\nas potential therapeutics in the treatment\nof Type 2 diabetes and obesity","volume":"12","author":"Zhang","year":"2003","journal-title":"Expert Opin.\nInvestig. Drugs."},{"issue":"9","key":"2026100610465604900_cit39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.drudis.2007.03.011","article-title":"PTP1B as a drug target: recent developments\nin PTP1B\ninhibitor discovery","volume":"12","author":"Zhang","year":"2007","journal-title":"Drug Discovery Today"},{"issue":"51","key":"2026100610465604900_cit40","doi-asserted-by":"publisher","first-page":"47771","DOI":"10.1074\/jbc.C100583200","article-title":"TYK2 and\nJAK2 are substrates of protein-tyrosine phosphatase 1B","volume":"276","author":"Myers","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"2026100610465604900_cit41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cmet.2011.09.011","article-title":"Elevated hypothalamic TCPTP in obesity contributes\nto cellular leptin resistance","volume":"14","author":"Loh","year":"2011","journal-title":"Cell Metab."},{"issue":"1","key":"2026100610465604900_cit42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1021\/acs.accounts.6b00537","article-title":"Drugging\nthe Undruggable: Therapeutic Potential of Targeting Protein Tyrosine\nPhosphatases","volume":"50","author":"Zhang","year":"2017","journal-title":"Acc. Chem. Res."},{"issue":"7984","key":"2026100610465604900_cit43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41586-023-06575-7","article-title":"The PTPN2\/PTPN1 inhibitor\nABBV-CLS-484 unleashes potent anti-tumour immunity","volume":"622","author":"Baumgartner","year":"2023","journal-title":"Nature"},{"issue":"5","key":"2026100610465604900_cit44","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1021\/acsptsci.4c00054","article-title":"Site-Specifically Modified Peptide Inhibitors\nof Protein Tyrosine\nPhosphatase 1B and T-Cell Protein Tyrosine Phosphatase with Enhanced\nStability and Improved In Vivo Long-Acting Activity","volume":"7","author":"Zhang","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"8","key":"2026100610465604900_cit45","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1021\/acs.jmedchem.1c00032","article-title":"Exendin 4-Hapten\nConjugate Capable of Binding with Endogenous Antibodies for Peptide\nHalf-life Extension and Exerting Long-Acting Hypoglycemic Activity","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026100610465604900_cit46","doi-asserted-by":"publisher","first-page":"11174","DOI":"10.1021\/acs.jmedchem.5c00147","article-title":"Dual Conjugation of\nLong- and Medium-Chain Fatty Acids\nto BimBH3 Peptide Yields Ultra Long-Acting Inhibitors of Intracellular\nPTPN1\/2","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026100610465604900_cit47","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug Metabolism\nand Variability among Patients in Drug Response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.6c05930","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/59556\/68612099\/acsomega.6c05930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/59556\/68612099\/acsomega.6c05930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:30:50Z","timestamp":1791300650000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/11\/39\/59556\/5436076\/The-PTPN1-N2-Peptide-Inhibitor-Achieves-Potent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":47,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.6c05930","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}